A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

Clinical trial NCT00871780 · COMPLETED

Trial details

NCT number: NCT00871780
Sponsor: Biogen
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Relapsing Remitting Multiple Sclerosis (RRMS)

Start date: 2009-08-01
Primary completion: 2012-07-01
Enrollment: 224

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.